✦ LIBER ✦

Successful repeat therapy with rituximab for relapsed thrombotic thrombocytopenic purpura

✍ Scribed by Wilmar Patino; Ravindra Sarode

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 141 KB
Volume: 22
Category: Article
ISSN: 0733-2459
DOI: 10.1002/jca.20113

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a life‐threatening disease that is treated successfully with therapeutic plasma exchange (TPE) and often with corticosteroids; however, almost one third of TTP patients have treatment failures that require either long‐term TPEs or other adjunct therapies. Recent insights into the autoimmune‐pathophysiology of this disease provide the rationale for immune‐based therapies. Cumulative evidence suggests that rituximab, an anti‐CD20 antibody that depletes B‐cells temporarily, is an effective therapy in patients with refractory or relapsing TTP. We report here two patients with chronic relapsing TTP who were treated successfully with rituximab. However, both experienced TTP relapse following sustained and prolonged remissions for 21 and 37 months, respectively. They responded favorably with repeat therapy with rituximab. The benefits of rituximab treatment for refractory or relapsing TTP as well as in the prevention of recurrences are discussed. J. Clin. Apheresis. 22:, 2007 © 2007 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Rituximab for treatment of refractory/re

Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP)

✍ Afaq Ahmad; Anita Aggarwal; Daya Sharma; Harish P. Dave; Virginia Kinsella; Marg 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views

## Abstract Plasma exchange is the standard treatment for thrombotic thrombocytopenic purpura (TTP). For patients refractory to plasma exchange, treatment options are limited and often unsuccessful. The platelet thrombi that form in acquired TTP are believed to result from the presence of procoagul

Cyclosporine therapy in refractory/relap

Cyclosporine therapy in refractory/relapsed patients with thrombotic thrombocytopenic purpura

✍ Annamaria Nosari; Rosaria Redaelli; Teresa Maria Caimi; Gianni Mostarda; Enrica 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 289 KB 👁 2 views

To the editor: The interesting article by van Beers et al. states that functional studies does not offer clues as to the presence of mild pulmonary hypertension (PH) in patients with sickle cell disease (SCD) [1]. However, they did show that although not statistically significant, lung function find

Rituximab therapy in two children with a

Rituximab therapy in two children with autoimmune thrombotic thrombocytopenic purpura

✍ Jumana H. Albaramki; Juliana Teo; Stephen I. Alexander 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 132 KB

Chronic relapsing thrombotic thrombocyto

Chronic relapsing thrombotic thrombocytopenic purpura: Role of therapy with cyclosporine

✍ Pasquale, Donald; Vidhya, Rakesh; DaSilva, Karen; Tsan, Min-Fu; Lansing, Lawrenc 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 31 KB 👁 2 views

Relapsing thrombotic thrombocytopenic purpura (TTP) is a rare disorder with most individuals experiencing 1 to 5 relapses. We report a patient with 18 episodes of thrombotic thrombocytopenic purpura (TTP), the highest number of relapses thus far described. The last 11 episodes were treated with regi

Successful treatment of severe thromboti

Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab

✍ Jens Chemnitz; Andreas Draube; Christof Scheid; Peter Staib; Armin Schulz; Volke 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB 👁 1 views

Therapy of chronic relapsing thrombotic

Therapy of chronic relapsing thrombotic thrombocytopenic purpura with prednisone and azathioprine

✍ Joel L. Moake; Christine K. Rudy; Joseph H. Troll; Andrew I. Schafer; Mark J. We 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 750 KB